Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

aTyr Pharma, Inc. - Common Stock (NQ:ATYR)

5.530 +0.230 (+4.34%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about aTyr Pharma, Inc. - Common Stock

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
No safety concerns identified by independent data and safety monitoring board (DSMB), which recommends continuation of study without any modifications. 
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
Management to host conference call and webcast on March 13th at 5:00 pm EDT / 2:00 pm PDT 
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
Independent data and safety monitoring board (DSMB) review includes all 268 patients who have been enrolled in the study and recommends continuation of study without any modifications. 
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
ATYR0101 interacts with LTBP-1 to induce myofibroblast apoptosis through a novel anti-fibrotic mechanism to reduce fibrosis and fibrotic markers in models of lung and kidney fibrosis. 
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma to Present at Upcoming Investor Conferences
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma to Participate in September Investor Conferences
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma Announces Research Study with Stanford Medicine
Study to explore role of the Company’s anti-NRP2 antibodies in glioblastoma multiforme (GBM), the most common type of primary brain cancer. 
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
From aTyr Pharma, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.